$3 B

FOLD Mkt cap, 22-Jun-2018
Amicus Therapeutics EBIT (Q1, 2018)-56.2 M
Amicus Therapeutics Cash, 31-Mar-2018114.3 M

Amicus Therapeutics Financials

Amicus Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

122.2 m1.2 m5 m36.9 m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833 k6.2 m

Gross profit

4.1 m30.7 m

Gross profit Margin, %

83%83%

R&D expense

104.8 m149.3 m

General and administrative expense

71.2 m88.7 m

Operating expense total

175.9 m472.7 m

Depreciation and amortization

3.6 m

EBIT

(405.6 m)(68.7 m)(130.4 m)(181.9 m)(442 m)

EBIT margin, %

(332%)(5613%)(3669%)(1197%)

Interest expense

46 k1.5 m1.6 m5.4 m17.2 m

Interest income

174 k223 k929 k1.6 m4.1 m

Pre tax profit

(449.1 m)

Income tax expense

3.5 m1.1 m1.1 m3.7 m165.1 m

Net Income

(378.5 m)(68.9 m)(132.1 m)(200 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

39 k456 k475 k293 k456 k475 k293 k

Cost of goods sold

344 k775 k1.8 m

R&D expense

10.1 m10 m10 m12 m16.1 m17.2 m21 m23.4 m18.3 m32.5 m30.9 m

General and administrative expense

4.6 m5.2 m4.8 m5.3 m6.4 m8.3 m15.4 m15.7 m19.3 m17.5 m19.1 m

Operating expense total

15.2 m16.1 m14.7 m17.1 m24.1 m26.9 m38 m43 m48.5 m46.7 m55.4 m284.3 m

EBIT

(15.1 m)(15.6 m)(14.3 m)(16.8 m)(24.1 m)(26.9 m)(38 m)(43 m)(48.5 m)(44.9 m)(52 m)(275.2 m)

EBIT margin, %

(38808%)(3426%)(3003%)(5739%)(5276%)(5672%)(12985%)

Interest expense

7 k355 k374 k377 k372 k338 k17 k945 k1.1 m1.5 m4.3 m4.4 m

Interest income

36 k42 k36 k55 k171 k158 k316 k307 k331 k460 k759 k1.2 m

Income tax expense

453 k253 k(56 k)

Net Income

(14.6 m)(15.9 m)(14.6 m)(17.1 m)(24.3 m)(27.1 m)(37.8 m)(43.7 m)(51.1 m)(46.7 m)(55 m)(214.8 m)

Amicus Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

43.6 m24.1 m69.5 m187 m49.1 m

Accounts Receivable

1.3 m9.5 m

Inventories

5.5 m2.9 m2.6 m3.4 m4.6 m

Current Assets

88.3 m154.6 m216.6 m340.1 m392 m

Goodwill

11.6 m11.6 m197.8 m197.8 m197.8 m

Total Assets

127.6 m210 m908.4 m1 b627 m

Accounts Payable

10.2 m16.3 m32.2 m185.5 m

Short-term debt

Current Liabilities

10.5 m20.2 m73.6 m111 m70 m

Long-term debt

Additional Paid-in Capital

423.6 m568.7 m917.5 m1.1 b1.4 b

Retained Earnings

(447.4 m)(579.6 m)(779.6 m)(1.1 b)

Total Equity

45.8 m122.2 m347.8 m360.2 m352.9 m

Financial Leverage

2.8 x1.7 x2.6 x2.9 x1.8 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

30 m27.5 m41.9 m19.7 m28.8 m249 m19.4 m23.5 m63.7 m33.1 m44.8 m37.4 m64.1 m114.3 m

Accounts Receivable

864 k1.9 m3.8 m6 m10.8 m

Inventories

194 k3.3 m3.7 m3.9 m7.3 m8.1 m

Current Assets

64.3 m73.5 m79.4 m87.2 m151.3 m365 m240.1 m168.5 m217.7 m221.7 m296.2 m241 m431 m592 m

Goodwill

11.6 m11.6 m11.6 m11.6 m11.6 m207.6 m197.8 m197.8 m197.8 m197.8 m197.8 m197.8 m197.8 m

Total Assets

69.1 m112.4 m118 m125.5 m192.6 m403.9 m986.7 m862.9 m914 m918.2 m993.4 m939 m680.8 m870 m

Accounts Payable

8.2 m9.2 m9.9 m11.3 m15.8 m16.9 m30.6 m22.5 m23.8 m29 m

Current Liabilities

8.6 m9.4 m11.2 m13.8 m21 m16.9 m35.9 m64.4 m80.5 m85.6 m109.6 m100.7 m68.2 m140.7 m

Total Liabilities

348.4 m

Additional Paid-in Capital

392.2 m424.8 m444.6 m468.7 m574.8 m826.6 m914.3 m921.2 m990 m1 b1.1 b1.1 b1.4 b1.6 b

Retained Earnings

(409.1 m)(426.2 m)(471.7 m)(498.9 m)(536.7 m)(623.3 m)(674.3 m)(721 m)(834.6 m)(882.7 m)(994.4 m)(1.1 b)

Total Equity

26.5 m31.1 m36.3 m43.3 m104 m328.9 m378.8 m311.6 m334.2 m336.6 m310.8 m266.9 m409.7 m521.6 m

Financial Leverage

2.6 x3.6 x3.2 x2.9 x1.9 x1.2 x2.6 x2.8 x2.7 x2.7 x3.2 x3.5 x1.7 x1.7 x

Amicus Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(59.6 m)(68.9 m)(132.1 m)(200 m)(284 m)

Depreciation and Amortization

1.7 m1.5 m1.8 m3.2 m3.6 m

Accounts Receivable

(1.4 m)(7.7 m)

Inventories

(3.2 m)2.3 m308 k(3.7 m)(897 k)

Accounts Payable

6.2 m15.5 m7.1 m

Cash From Operating Activities

(45.8 m)(51.7 m)(100.1 m)(150.5 m)(215.5 m)

Purchases of PP&E

(695 k)(238 k)(4.8 m)(6 m)(4.5 m)

Cash From Investing Activities

(145.3 m)(4.5 m)(171.2 m)

Cash From Financing Activities

139.2 m290.9 m272.7 m247.4 m

Interest Paid

30 k1.2 m605 k3 m7.4 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(47.4 m)(15.9 m)(30.6 m)(47.7 m)(24.3 m)(51.4 m)(89.2 m)(43.7 m)(94.7 m)(141.4 m)(55 m)(103.1 m)(214.8 m)(49.9 m)

Depreciation and Amortization

1.3 m412 k808 k1.2 m508 k861 k1.3 m673 k1.4 m2.3 m823 k1.6 m969 k

Accounts Receivable

(863 k)(512 k)(2.2 m)6 m(1 m)

Inventories

(207 k)(3.5 m)(243 k)(351 k)7.3 m(3.3 m)

Accounts Payable

(679 k)(987 k)(155 k)1.2 m(551 k)459 k14.1 m(9.8 m)(8.2 m)(2.9 m)(1.3 m)

Cash From Operating Activities

(37.7 m)(10.2 m)(22 m)(37.2 m)(21 m)(43.6 m)(64.6 m)(44.9 m)(77.7 m)(118.5 m)(49.8 m)(91.8 m)(141.7 m)(49.5 m)

Purchases of PP&E

(645 k)(40 k)(132 k)(192 k)(753 k)(1.4 m)(2.2 m)(2.9 m)(4.6 m)(5.5 m)(732 k)(2.3 m)

Cash From Investing Activities

(5.8 m)2.1 m(27.3 m)31.3 m(230.7 m)(39.9 m)(92.4 m)(48.9 m)(222.8 m)(182.6 m)

Cash From Financing Activities

(85 k)18.2 m40.5 m4.1 m237.2 m290.7 m82.8 m122.4 m(95 k)240.6 m296.6 m

Interest Paid

24 k208 k537 k864 k209 k605 k605 k209 k276 k284 k12 k3.7 m3.7 m12 k

Free Cash Flow

(50.3 m)

Amicus Therapeutics Ratios

USDY, 2018

Financial Leverage

1.7 x
Report incorrect company information